Deals and M&A

Miracogen expands ADC deal with Synaffix

January 21, 2020

HONG KONG – In less than a year, China-based Shanghai Miracogen Inc. has extended its partnership with Oss, the Netherlands based Synaffix BV for a second antibody-drug conjugate (ADCs) candidate. The new deal is similar to one signed last year in that it gives Miracogen nonexclusive rights to Synaffix’s Glycoconnect and Hydraspace ADC technologies for use in a second clinical candidate.

Oncologie boosts pipeline with phase II-ready bispecific candidate in Mereo deal

January 21, 2020

By Elise Mak

No Comments

BEIJING – In a deal that adds another clinical-stage program to its pipeline, U.S.-China biotech Oncologie Inc. has picked up global rights to phase II-ready anti-DLL4/VEGF bispecific antibody navicixizumab from London-based Mereo Biopharma Group plc.

Aum Biosciences partners with Cyclica for cancer therapies development

January 21, 2020

By Jihyun Kim and Elise Mak

No Comments

HONG KONG - Singapore-based biotech Aum Biosciences Pte. Ltd., and Toronto, Canada-based biotech Cyclica Inc. have agreed to work together to apply Cyclica’s drug discovery platform in Aum’s R&D programs for the discovery of potential new cancer therapies. Aum will deploy its drug R&D skills including a biomarker-driven approach while Cyclica will contribute its AI-augmented platforms, Ligand Design and Ligand Express.

M&As and deals up overall in 2019 for med tech, an investor haven in 2020

January 17, 2020

By Karen Carey

No Comments

Last year’s robust deal-making environment, high-value M&As, increasing financings and a supportive public market has set the stage for continued med-tech enthusiasm among investors and partners in 2020.

Biontech acquires Neon in $67M all-stock deal to strengthen T-cell portfolio

January 16, 2020

By Michael Fitzhugh

No Comments

SAN FRANCISCO – Following years of mutual admiration, Germany's Biontech SE is moving to acquire Cambridge, Mass.-based Neon Therapeutics Inc., a neoantigen-based T-cell therapy specialist, in an all-stock transaction valued at about $67 million.

Oncologie boosts pipeline with phase II-ready bispecific candidate in Mereo deal

January 16, 2020

By Elise Mak

No Comments

BEIJING – In a deal that adds another clinical-stage program to its pipeline, U.S.-China biotech Oncologie Inc. has picked up global rights to phase II-ready anti-DLL4/VEGF bispecific antibody navicixizumab from London-based Mereo Biopharma Group plc.

Miracogen expands ADC deal with Synaffix

January 15, 2020

By David Ho and Elise Mak

No Comments

HONG KONG – In less than a year, China-based Shanghai Miracogen Inc. has extended its partnership with Oss, the Netherlands based Synaffix BV for a second antibody-drug conjugate (ADCs) candidate. The new deal is similar to one signed last year in that it gives Miracogen nonexclusive rights to Synaffix’s Glycoconnect and Hydraspace ADC technologies for use in a second clinical candidate.

Targovax scores potential $100M KRAS vaccine deal in China

January 14, 2020

By Cormac Sheridan

No Comments

DUBLIN – Shares in Targovax ASA rose as much as 26% last Wednesday on news of an option and license agreement in China involving its peptide-based KRAS-directed cancer vaccines, TG-01 and TG-02.

In with the new

Boehringer inks $1B+ antifibrosis deal with Singapore's Enleofen Bio

January 14, 2020

By Michael Fitzhugh

No Comments

Fresh off ending one antifibrosis program in December, Boehringer Ingelheim GmbH (BI) is spinning up an expansive new effort in the area this month, promising Singapore-based Enleofen Bio Pte. Ltd. potential payouts of more than $1 billion per product from a preclinical interleukin-11 platform.

Gennbio licenses in two immunosuppressants valued up to $164M from Genexine

January 14, 2020

By Jihyun Kim

No Comments

Gennbio Co. Ltd. has signed an agreement with fellow Korean biotech Genexine Inc. to in-license two immunosuppressant drug candidates called GX-P1 (PD-L1 hyfc) and BSF-110 (PD-L1-hyFc-1L10m).